Otsuka Commits $800M in M&A Deal Bringing a Phase 3-Ready Metabolic Disorder Drug
[[{“value”:” Otsuka Pharmaceutical is acquiring Jnana Therapeutics, whose lead drug is a potential treatment for the rare metabolic disorder phenylketonuria …
Otsuka Commits $800M in M&A Deal Bringing a Phase 3-Ready Metabolic Disorder Drug Read More »